Molecular Determinants of Multi-nucleoside Analogue Resistance in HIV-1 Reverse Transcriptases Containing a Dipeptide Insertion in the Fingers Subdomain

Human immunodeficiency virus type 1 isolates having dipeptide insertions in the fingers subdomain of the reverse transcriptase (RT) show high level resistance to 3 ′-azido-3 ′-deoxythymidine (AZT) and other nucleoside analogues. Insertions are usually associated with thymidine analogue resistance mutations, such as T215Y. The resistance phenotype correlates with increased ATP-dependent phosphorolytic activity, which facilitates removal of thymidine analogues from inhibitor-terminated primers. In this report, we show that substituting Thr, Ser, or Asn for Tyr-215 in a multidrug-resistant RT, bearing a Ser-Ser insertion between codons 69 and 70, leads to AZT and stavudine resensitization through the loss of the ATP-mediated removal activity. The mutation D67N, which is rarely found in insertion-containing strains, had no effect on excision and a minor influence on resistance. Substituting Tyr-215 had a larger effect than deleting the dipeptide insertion. The presence of both the insertion and mutation T215Y in the wild-type BH10 RT conferred significant ATP-mediated removal activity and moderate resistance to AZT. However, resistance levels and unblocking activities were lower than those observed with the multidrug-resistant enzyme. Removal reactions can be inhibited by the next complementary dNTP. Both Tyr-215 and the dipeptide insertion affect RT-DNA·DNA-dNTP ternary complex formation, an effect that was not detected in the presence of foscarnet. Based on crystal structures of binary and ternary complexes of HIV-1 RT, we propose that Tyr-215 exerts its action by facilitating a proper orientation of the pyrophosphate donor molecule, whereas the effects on dNTP binding are indirect and could be related to significant conformational changes occurring during polymerization.

[1]  F. Brun-Vézinet,et al.  Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants , 1998, Journal of Virology.

[2]  E. Domingo,et al.  Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. , 2000, Virus research.

[3]  Kamalendra Singh,et al.  Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. , 2002, Biochemistry.

[4]  J Desmyter,et al.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.

[5]  Bikram Chakraborty,et al.  Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation , 2002, Journal of Virology.

[6]  A. Mian,et al.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. , 1999, Molecular cell.

[7]  R. D. de Boer,et al.  Establishment of New Transmissible and Drug-Sensitive Human Immunodeficiency Virus Type 1 Wild Types due to Transmission of Nucleoside Analogue-Resistant Virus , 2001, Journal of Virology.

[8]  T. Merigan,et al.  Genotypic, Phenotypic, and Modeling Studies of a Deletion in the β3-β4 Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene That Is Associated with Resistance to Nucleoside Reverse Transcriptase Inhibitors , 2000, Journal of Virology.

[9]  S. Sharma,et al.  Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. , 1997, Biochemistry.

[10]  K. Anderson,et al.  Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. , 2003, Biochemistry.

[11]  S. Swaminathan,et al.  Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations , 2004, Antimicrobial Agents and Chemotherapy.

[12]  Colombe Chappey,et al.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.

[13]  A. D. Clark,et al.  Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Schooley,et al.  Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.

[15]  E. De Clercq,et al.  Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues , 2000, Antimicrobial Agents and Chemotherapy.

[16]  L. Menéndez-Arias Targeting HIV: antiretroviral therapy and development of drug resistance. , 2002, Trends in pharmacological sciences.

[17]  R de Boer,et al.  Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.

[18]  B. Larder,et al.  Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. , 1994, The Journal of general virology.

[19]  L. Naeger,et al.  ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2002, Antimicrobial Agents and Chemotherapy.

[20]  B. Larder,et al.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.

[21]  D. Katzenstein,et al.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. , 1998, The Journal of clinical investigation.

[22]  R. D. de Boer,et al.  Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. , 2001, AIDS research and human retroviruses.

[23]  D. I. Stuart,et al.  Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215 , 2002, Journal of Virology.

[24]  T. Merigan,et al.  Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years , 1997, Antimicrobial agents and chemotherapy.

[25]  E. Arnold,et al.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Marchand,et al.  Site-specific Footprinting Reveals Differences in the Translocation Status of HIV-1 Reverse Transcriptase , 2003, Journal of Biological Chemistry.

[27]  D. Stuart,et al.  3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Sarafianos,et al.  Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse Transcriptase , 2001, Journal of Virology.

[29]  B. Larder,et al.  Effects of Dipeptide Insertions between Codons 69 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Primer Unblocking, Deoxynucleoside Triphosphate Inhibition, and DNA Chain Elongation , 2003, Journal of Virology.

[30]  Miguel Ángel Martínez,et al.  Role of a dipeptide insertion between codons 69 and 70 of HIV‐1 reverse transcriptase in the mechanism of AZT resistance , 2000, The EMBO journal.

[31]  E. Domingo,et al.  Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115. , 1997, Nucleic acids research.

[32]  R. Schinazi,et al.  Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates , 2000, Antimicrobial Agents and Chemotherapy.

[33]  A. So,et al.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Fantini,et al.  Stable rearrangements of the β3–β4 hairpin loop of HIV‐1 reverse transcriptase in plasma viruses from patients receiving combination therapy , 1998, AIDS.

[35]  M. Parniak,et al.  Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. , 1998, Biochemistry.

[36]  C. M. Joyce,et al.  Deoxynucleoside Triphosphate and Pyrophosphate Binding Sites in the Catalytically Competent Ternary Complex for the Polymerase Reaction Catalyzed by DNA Polymerase I (Klenow Fragment) (*) , 1995, The Journal of Biological Chemistry.

[37]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[38]  E. Domingo,et al.  Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. , 1996, The EMBO journal.

[39]  J. Erickson,et al.  Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.

[40]  A. D. Clark,et al.  Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. , 1998, Journal of molecular biology.

[41]  W. Rozenbaum,et al.  Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[42]  A. D. Clark,et al.  Structures of HIV‐1 reverse transcriptase with pre‐ and post‐translocation AZTMP‐terminated DNA , 2002, The EMBO journal.

[43]  Miguel Ángel Martínez,et al.  Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase. , 1999, Journal of molecular biology.

[44]  B. Larder,et al.  Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates , 2002, Antimicrobial Agents and Chemotherapy.

[45]  S. Sarafianos,et al.  Nucleoside Analog Resistance Caused by Insertions in the Fingers of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involves ATP-Mediated Excision , 2002, Journal of Virology.

[46]  V. Calvez,et al.  Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors , 2001, Antimicrobial Agents and Chemotherapy.

[47]  L. Menéndez-Arias,et al.  Coupling Ribose Selection to Fidelity of DNA Synthesis , 2000, The Journal of Biological Chemistry.

[48]  J. Mellors,et al.  Relationship between 3′-Azido-3′-Deoxythymidine Resistance and Primer Unblocking Activity in Foscarnet-Resistant Mutants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2003, Journal of Virology.

[49]  T. Merigan,et al.  Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy , 1996, Journal of virology.

[50]  E. Domingo,et al.  Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. , 2002, Journal of molecular biology.

[51]  D. Stuart,et al.  A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[52]  N. Sluis-Cremer,et al.  Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) , 2000, Cellular and Molecular Life Sciences (CMLS).

[53]  W. Heneine,et al.  Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Stammers,et al.  Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine , 2001, Antimicrobial Agents and Chemotherapy.

[55]  J. Mellors,et al.  Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2002, Antimicrobial Agents and Chemotherapy.

[56]  P. Massip,et al.  Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine , 1999, Journal of medical virology.

[57]  E. De Clercq,et al.  The HIV‐1 Reverse Transcription (RT) Process as Target for RT Inhibitors , 2000, Medicinal research reviews.

[58]  B. Canard,et al.  Nucleotide Analogue Binding, Catalysis and Primer Unblocking in the Mechanisms of HIV-1 Reverse Transcriptase-Mediated Resistance to Nucleoside Analogues , 2002, Antiviral therapy.

[59]  L. Naeger,et al.  Increased Drug Susceptibility of HIV-1 Reverse Transcriptase Mutants Containing M184V and Zidovudine-Associated Mutations: Analysis of Enzyme Processivity, Chain-Terminator Removal and Viral Replication , 2000, Antiviral therapy.